Changes in Infectious Disease Mortality in Children During the Past Three Decades

The Pediatric Infectious Disease Journal
September 2013 – Volume 32 – Issue 9  pp: A15,931-1044,e348-e382
http://journals.lww.com/pidj/pages/currenttoc.aspx

Changes in Infectious Disease Mortality in Children During the Past Three Decades
Lantto, Marjo; Renko, Marjo; Uhari, Matti

Abstract
Background: Our aim was to evaluate changes in infectious disease mortality in children in Finland from 1969 to 2004. We especially wanted to find out whether infection mortality could be further reduced by means of existing vaccines not included in national vaccination program.

Methods: We analyzed infectious disease mortality in Finland using data obtained from the official Cause of Death statistics for 1969 to 2004. Annual mortality rates were calculated in proportion to those at risk of dying. Infection mortality rates were calculated separately for neonates and children who were 1 month to 15 years.

Results: Childhood mortality due to infectious diseases decreased by 89%, from 0.12% in 1969 to 0.013% in 2004, and neonatal mortality by 69%, from 0.50% to 0.16%. Pneumonia, central nervous system infections and septicemia were the most common fatal infections in childhood. There were slightly more deaths due to all infections and respiratory tract infections in years marked by epidemics of respiratory syncytial virus. We estimated that pneumococcal conjugate vaccines would have prevented 2 deaths annually in our population, rotavirus vaccines 1 to 2 deaths, influenza vaccine 1 death and varicella vaccine 0.7 death.

Conclusions: We found that even though mortality from infectious diseases in childhood decreased markedly during the period concerned, it could have been further reduced by means of existing vaccines. Even though the number of deaths prevented would have been small, the number of years of life saved would have been great because the life expectancy of children is long.

A Qualitative Analysis of Factors Influencing HPV Vaccine Uptake in Soweto, South Africa among Adolescents and Their Caregiv

PLoS One
[Accessed 31 August 2013]
http://www.plosone.org/

Research Article
A Qualitative Analysis of Factors Influencing HPV Vaccine Uptake in Soweto, South Africa among Adolescents and Their Caregivers
Ingrid T. Katz mail, Busisiwe Nkala, Janan Dietrich, Melissa Wallace, Linda-Gail Bekker, Kathryn Pollenz, Laura M. Bogart, Alexi A. Wright, Alexander C. Tsai, David R. Bangsberg, Glenda E. Gray
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0072094

Abstract
Background
In South Africa, the prevalence of oncogenic Human Papillomavirus (HPV) may be as high as 64%, and cervical cancer is the leading cause of cancer-related death among women. The development of efficacious prophylactic vaccines has provided an opportunity for primary prevention. Given the importance of psycho-social forces in vaccine uptake, we sought to elucidate factors influencing HPV vaccination among a sample of low-income South African adolescents receiving the vaccine for the first time in Soweto.

Methods
The HPV vaccine was introduced to adolescents in low-income townships throughout South Africa as part of a nationwide trial to understand adolescent involvement in future vaccine research targeting human immunodeficiency virus (HIV). We performed in-depth semi-structured interviews with purposively-sampled adolescents and their care providers to understand what forces shaped HPV vaccine uptake. Interviews were recorded, transcribed, translated, and examined using thematic analysis.

Results
Of 224 adolescents recruited, 201 initiated the vaccine; 192 (95.5%) received a second immunization; and 164 (81.6%) completed three doses. In our qualitative study of 39 adolescent-caregiver dyads, we found that factors driving vaccine uptake reflected a socio-cultural backdrop of high HIV endemnicity, sexual violence, poverty, and an abundance of female-headed households. Adolescents exercised a high level of autonomy and often initiated decision-making. Healthcare providers and peers provided support and guidance that was absent at home. The impact of the HIV epidemic on decision-making was substantial, leading participants to mistakenly conflate HPV and HIV.

Conclusions
In a setting of perceived rampant sexual violence and epidemic levels of HIV, adolescents and caregivers sought to decrease harm by seeking a vaccine targeting a sexually transmitted infection (STI). Despite careful consenting, there was confusion regarding the vaccine’s target. Future interventions promoting STI vaccines will need to provide substantial information for participants, particularly adolescents who may exercise a significant level of autonomy in decision-making.

Timeliness Vaccination of Measles Containing Vaccine and Barriers to Vaccination among Migrant Children in East Chin

PLoS One
[Accessed 31 August 2013]
http://www.plosone.org/

Research Article
Timeliness Vaccination of Measles Containing Vaccine and Barriers to Vaccination among Migrant Children in East China
Yu Hu mail, Qian Li, Shuying Luo, Linqiao Lou, Xiaohua Qi, Shuyun Xie
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0073264

Abstract
Background
The reported coverage rates of first and second doses of measles containing vaccine (MCV) are almost 95% in China, while measles cases are constantly being reported. This study evaluated the vaccine coverage, timeliness, and barriers to immunization of MCV1 and MCV2 in children aged from 8–48 months.

Methods
We assessed 718 children aged 8–48 months, of which 499 children aged 18–48 months in September 2011. Face to face interviews were administered with children’s mothers to estimate MCV1 and MCV2 coverage rate, its timeliness and barriers to vaccine uptake.

Results
The coverage rates were 76.9% for MCV1 and 44.7% for MCV2 in average. Only 47.5% of surveyed children received the MCV1 timely, which postpone vaccination by up to one month beyond the stipulated age of 8 months. Even if coverage thus improves with time, postponed vaccination adds to the pool of unprotected children in the population. Being unaware of the necessity for vaccination and its schedule, misunderstanding of side-effect of vaccine, and child being sick during the recommended vaccination period were significant preventive factors for both MCV1 and MCV2 vaccination. Having multiple children, mother’s education level, household income and children with working mothers were significantly associated with delayed or missing MCV1 immunization.

Conclusions
To avoid future outbreaks, it is crucial to attain high coverage levels by timely vaccination, thus, accurate information should be delivered and a systematic approach should be targeted to high-risk groups.

Addressing Ethical, Social, and Cultural Issues in Global Health Research

PLoS Neglected Tropical Diseases
August 2013
http://www.plosntds.org/article/browseIssue.action

Policy Platform
Addressing Ethical, Social, and Cultural Issues in Global Health Research
James V. Lavery mail, Shane K. Green, Sunita V. S. Bandewar, Anant Bhan, Abdallah Daar, Claudia I. Emerson, Hassan Masum, Filippo M. Randazzo, Jerome A. Singh, Ross E. G. Upshur, Peter A. Singer
http://www.plosntds.org/article/info%3Adoi%2F10.1371%2Fjournal.pntd.0002227;jsessionid=04509CEF62F57E8BDF1743A89C443DDF

Summary
The purpose of this paper is to encourage reflection among the global health research community and the research ethics community about how a wide range of ethical, social, and cultural (ESC) influences on the conduct, success, and impact of global health research can best be addressed by consultation services in research ethics (CSRE). We draw on lessons we have learned during our experiences with the ESC Program of the Grand Challenges in Global Health initiative to propose key features of CSRE that may prove useful for those designing or implementing similar programs.

Poverty Impedes Cognitive Function

Science        
30 August 2013 vol 341, issue 6149, pages 929-1032
http://www.sciencemag.org/current.dtl

Research Article
Poverty Impedes Cognitive Function
Anandi Mani1, Sendhil Mullainathan2,*, Eldar Shafir3,*, Jiaying Zhao4
+ Author Affiliations
1Department of Economics, University of Warwick, Coventry CV4 7AL, UK.
2Department of Economics, Harvard University, Cambridge, MA 02138, USA.
3Department of Psychology and Woodrow Wilson School of Public and International Affairs, Princeton University, Princeton, NJ 08540, USA.
4Department of Psychology and Institute for Resources, Environment and Sustainability, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada.
*Corresponding author. E-mail: mullain@fas.harvard.edu (S.M.); shafir@princeton.edu (E.S.)
http://www.sciencemag.org/content/341/6149/976.abstract

Abstract
The poor often behave in less capable ways, which can further perpetuate poverty. We hypothesize that poverty directly impedes cognitive function and present two studies that test this hypothesis. First, we experimentally induced thoughts about finances and found that this reduces cognitive performance among poor but not in well-off participants. Second, we examined the cognitive function of farmers over the planting cycle. We found that the same farmer shows diminished cognitive performance before harvest, when poor, as compared with after harvest, when rich. This cannot be explained by differences in time available, nutrition, or work effort. Nor can it be explained with stress: Although farmers do show more stress before harvest, that does not account for diminished cognitive performance. Instead, it appears that poverty itself reduces cognitive capacity. We suggest that this is because poverty-related concerns consume mental resources, leaving less for other tasks. These data provide a previously unexamined perspective and help explain a spectrum of behaviors among the poor. We discuss some implications for poverty policy.

From Google Scholar+ [ to 31 August 2013]

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary\

Further Evidence for Bias in Observational Studies of Influenza Vaccine Effectiveness: The 2009 Influenza A (H1N1) Pandemic
ML Jackson, O Yu, JC Nelson, A Naleway, EA Belongia… – American Journal of …, 2013
Abstract Preinfluenza periods have been used to test for uncontrolled confounding in studies
of influenza vaccine effectiveness, but some authors have claimed that confounding differs
in preinfluenza and influenza periods. We tested this claim by comparing estimates of the

Risk Factors for Non-Initiation of the Human Papillomavirus (HPV) Vaccine among Adolescent Survivors of Childhood Cancer
J Klosky, K Russell, K Canavera, H Gammel… – Cancer Prevention …, 2013
Abstract Effective vaccination is now available to prevent human papillomavirus (HPV), the
most common sexually transmitted infection and cause of cervical cancer. This study aimed
to estimate the prevalence of HPV vaccination among childhood cancer survivors and

Vaccines: The Week in Review 24 August 2013

NOTICE: Vaccines: The Week in Review resumes publication on 24 August 2013 following duty travel by the editor.

Vaccines: The Week in Review is a weekly digest — summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated “29 June 2013″
.
Email Summary: Vaccines: The Week in Review is published as a single email summary, scheduled for release each Saturday eveningbefore midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.
.
pdf version: A pdf of the current issues is available here: Vaccines_The Week in Review_24 August 2013
.
Twitter: Readers can also follow developments on twitter: @vaxethicspolicy.
.
Links: We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.
.
Support: If you would like to join the growing list of individuals who support this service and its contribution to their roles in public health, clinical practice, government, IGOs/NGOs, research, industry and academia, please visit this page at The Wistar Institute, our co-founder and fiduciary. Thank you…
.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy
a program of the
– Division of Medical Ethics, NYU Medical School
– The Wistar Institute Vaccine Center
– Children’s Hospital of Philadelphia Vaccine Education Center
Associate Faculty, Division of Medical Ethics, NYU Medical School

GAVI/WHO/UNICEF: Indonesia introduces pentvalent pediatric vaccine

Joint GAVI/WHO/UNICEF News Release: “Indonesia introduces five-in-one vaccine for children”
22 August 2013, Jakarta, Indonesia

Excerpt
The pentavalent vaccine is part of “an ambitious plan to reach children across the country’s 6,000 inhabited islands by the end of next year” with GAVI support. The vaccine will be purchased from Bio Farma, an Indonesian vaccine supplier based in Bandung, “meaning that Indonesian children will benefit from Indonesian innovation.”
Full release: http://www.who.int/immunization/newsroom/indonesia_five_in_one_20130822/en/index.html

DFID to invest £138 million over 5 years into 9 public-private partnerships

  The U.K. Department for International Development (DFID) said it is investing £138 million over the next 5 years into 9 public-private partnerships “to support the development of innovative new drugs, vaccines, insecticides, diagnostic tools and microbicides… The partnerships will bring together experts in the field while also sharing the costs and risks across partners.” The nine Product Development Partnerships (PDPs) receiving support include [Editor’s bolded text]:

:: Drugs for Neglected Diseases initiative (DNDi): new drugs for sleeping sickness, skin sores, river blindness and other lymphatic diseases spread by parasites and mosquitoes

:: Medicines for Malaria Venture (MMV): new drugs for malaria, with a focus on treating malaria in pregnancy and the relapsing form of malaria

:: Innovative Vector Control Consortium (IVCC): new insecticides to control insects that carry malaria and some of the neglected tropical diseases

:: Foundation for Innovative New Diagnostics (FIND): new diagnostic tests for TB, malaria and sleeping sickness

:: TB Alliance: new drugs for people with TB and for those also infected with HIV

:: Aeras: development of new vaccines to prevent TB infection

:: New Products for Diarrhoea and Malaria (PATH): developing new drugs, diagnostics and vaccines for diarrhoeal disease and diagnostics for malaria

::: International AIDS Vaccine Initiative (IAVI): support for the development of new AIDS vaccines

::International Partnership for Microbicides (IPM): support for the development of women-controlled HIV prevention technologies.

https://www.gov.uk/government/news/dfid-invests-to-save-millions-from-deadly-diseases

WHO: First medicine for treatment of a neglected tropical disease receives prequalification

WHO: First medicine for treatment of a neglected tropical disease receives prequalification
20 August 2013
The United Nations Prequalification of Medicines Programme managed by WHO announced the prequalification of a 100 mg tablet of diethylcarbamazine which will be used in large-scale treatment of individuals at risk of lymphatic filariasis. Media release: http://apps.who.int/prequal/info_press/documents/PQ_1st_NTD_medicine.pdf

GPEI Update: Polio this week – As of 21 August 2013

Update: Polio this week – As of 21 August 2013
Global Polio Eradication Initiative
Full report: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx
[Editor’s extract and bolded text]

:: In Ethiopia, a case of WPV1 has been detected in an 18-month old child from the Somali Region (Warder district.) (see the Horn of Africa section for details)
:: In Israel, WPV1 has been detected in 68 sewage samples collected from 3 February 2013 to 16 August 2013 from 24 sampling sites. (see the Israel section for details)
:: In Somalia, eight new WPV1 cases have been reported this week from previously infected districts.

Pakistan
:: 1 new cVDPV2 case was reported in the past week from a new district, Mohmand, in FATA with the onset of paralysis on 13 July. The total number of cVDPV2 cases for 2013 is 12.
:: FATA remains the major poliovirus reservoir in Pakistan and in Asia, both due to WPV1 and cVDPV2.

Chad, Cameroon and Central African Republic
:: Central African Republic (CAR) continues to be at serious risk of re-infection due to proximity with Chad, ongoing insecurity and humanitarian crises, and destruction of health infrastructure. :: To minimize the risk and consequences of potential re-infection, two subnational immunization campaigns were conducted in June and July. A SNID is planned for September and a NID for October.

Horn of Africa
:: 11 new WPV1 cases were reported in the past week – in previously infected districts in Kenya and Somalia, and in a previously unaffected country, Ethiopia. The total number of WPV1 cases for 2013 is 121 (108 from Somalia,12 from Kenya, 1 from Ethiopia). The most recent WPV1 case in the region had onset of paralysis on 14 July (from Kenya).
:: On 14 August, a case of WPV1 was reported in a child living in Ethiopia with date of onset of paralysis of 10 July 2013. The case is an 18-month old child from the Somali Region (Warder district) of Ethiopia who had never been vaccinated with oral polio vaccine (OPV).
:: Because of the known routes of poliovirus spread in previous outbreaks in the Horn of Africa, the Somali region of Ethiopia had been considered at ‘high risk’, and since June, two large-scale supplementary immunization activities (SIAs) had already been conducted as part of the broader Horn of Africa outbreak response.
:: In Ethiopia, an immediate local immunization campaign is being conducted in the vicinity of the case, with a larger-scale SIA planned targeting 950,000 children under the age of five years. Additional SIAs are planned from September to November. Confirmation of the case in Ethiopia underscores the risk this outbreak continues to pose to countries across the region.
:: Access in some areas of south-central Somalia remains a significant challenge. Analysis shows that as many as 70% of children in inaccessible areas are under-immunized. This compares to 20% in accessible areas of the country. Of the 108 cases reported from Somalia so far, 33 are from inaccessible or only partially-accessible areas; 75 cases are from accessible areas or accessible areas with security challenges.
:: In Kenya, the priority remains on increasing immunity levels in the Dadaab area of North Eastern province. Nearly 50% of children in this area remain under-immunized (compared to less than 5% in Kenya on the whole).

Israel
:: WPV1 has been detected in 67 sewage samples from 24 sampling sites in Israel, collected from 3 February 2013 to 4 August 2013. Initially restricted to southern Israel, WPV1 has now also been detected in environmental sampling sites elsewhere in Israel, indicating widespread transmission throughout the country. No case of paralytic polio has been reported.
:: To interrupt WPV1 transmission, a supplementary immunization activity (SIA) with bivalent oral polio vaccine (OPV) targeting children up to the age of nine years was initiated in the southern district of Israel during the week of 5 August; since August 18, the SIA was expanded to the entire country. The objective of the SIA with OPV is to boost intestinal immunity in children vaccinated with IPV only in order to rapidly interrupt wild poliovirus transmission.

WHO: GAR- Poliovirus detected from environmental samples in Israel – update 15 August 2013

WHO: Global Alert and Response (GAR) – Disease Outbreak News
http://www.who.int/csr/don/2013_03_12/en/index.html
Disease outbreak news

Poliovirus detected from environmental samples in Israel – update 15 August 2013
   The World Health Organization (WHO) estimates the risk of further international spread of wild poliovirus type 1 (WPV1) from Israel to remain moderate to high. This risk assessment reflects evidence of increasing geographic extent of circulation over a prolonged period of time.

WPV1 has been detected in 67 sewage samples from 24 sampling sites in Israel, collected from 3 February 2013 to 4 August 2013. Initially restricted to southern Israel, WPV1 has now also been detected in the central district as well. WPV1 has also been isolated in stool samples from 27 healthy children (all under the age of nine years) and one adult, who had been fully immunized for their age as part of ongoing stool sample survey activities. No case of paralytic polio has been reported. In addition to routine acute flaccid paralysis, public health authorities have expanded the surveillance to all age groups and have increased enterovirus surveillance and are screening aseptic meningitis cases for polio.

A supplementary immunization activity (SIA) with bivalent oral polio vaccine (OPV) started in parts of southern Israel during the week of 5 August 2013, and a nationwide campaign is planned for 18 August 2013 for children up to the age of nine years. The objective of these SIAs with OPV is to boost mucosal immunity levels in cohorts of children naïve to OPV to rapidly interrupt virus circulation.

It is important that all countries, in particular those with frequent travel and contacts with polio affected countries, strengthen surveillance for cases of acute flaccid paralysis (AFP), in order to rapidly detect any new poliovirus importations and facilitate a rapid response. Countries should also analyze routine immunization coverage data to identify any subnational gaps in population immunity to guide catch-up immunization activities and thereby minimize the consequences of any new virus introduction. Priority should be given to areas at high-risk of importations and where OPV3/DPT3 vaccine coverage is less than 80 percent.

WHO’s International Travel and Health recommends that all travellers to and from poliovirus-affected areas be fully vaccinated against polio. Three countries remain endemic for indigenous transmission of WPV: Nigeria, Pakistan and Afghanistan. Additionally, in 2013, the Horn of Africa has been affected by an outbreak of WPV1.

http://www.who.int/csr/don/2013_08_15/en/index.html

Weekly Epidemiological Record (WER) for 23 & 16 August 2013

The Weekly Epidemiological Record (WER) for 16 August 2013, vol. 88, 33 (pp. 349–356) includes:
:: Poliomyelitis outbreak in Somalia and Kenya, 2013
http://www.who.int/entity/wer/2013/wer8833.pdf

   The WER for 23 August 2013, vol. 88, 34 (pp. 357–364) includes:
:: Japanese encephalitis: status of surveillance and immunization in Asia and the Western Pacific, 2012
http://www.who.int/entity/wer/2013/wer8834.pdf

MMWR: Polio Field Census and Vaccination of Underserved Populations — Northern Nigeria, 2012–2013

CDC/MMWR Watch [to 24 August 2013]
MMWR August 23, 2013 / Vol. 62 / No. 33
Polio Field Census and Vaccination of Underserved Populations — Northern Nigeria, 2012–2013
August 23, 2013 / 62(33);663-665

In 2012, the World Health Assembly declared completion of polio eradication a public health emergency (1,2). However, wild poliovirus (WPV) transmission remains endemic in three countries (Afghanistan, Nigeria, and Pakistan) (24). In Nigeria, the National Stop Transmission of Polio (N-STOP) program, under the umbrella of the Nigerian Field Epidemiology and Laboratory Training Program (FELTP), has been developed to implement innovative strategies that address the remaining polio eradication challenges in Nigeria. One N-STOP initiative focuses on locating and vaccinating children aged <5 years in remote nomadic, scattered, and border populations in northern Nigeria, where low polio vaccination coverage likely contributes to ongoing WPV transmission. During August 2012–April 2013, N-STOP conducted field outreach activities that enumerated 40,212 remote settlements, including 4,613 (11.5%) settlements never visited by vaccination teams during previous polio supplemental immunization activities (SIAs). Enumeration resulted in documentation of 906,201 children aged <5 years residing in these settlements, including 53,738 (5.9%) who had never received polio vaccination, and in detection of 211 unreported cases of acute flaccid paralysis (AFP) with onset of illness in the 6 months before enumeration. Sustaining access to underserved populations in remote settlements in future SIAs will increase overall population immunity and should decrease WPV transmission. By providing a flexible and capable workforce consisting of Nigerian citizens, N-STOP is able to support evaluation and implementation of innovative polio eradication strategies in Nigeria while building local public health capacity with a potential to address other public health problems following the eradication of polio from Nigeria.
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6233a3.htm?s_cid=mm6233a3_w

WHO SAGE: Call for nominations for SAGE Working Group on hepatitis E vaccine

WHO SAGE: Call for nominations for SAGE Working Group on hepatitis E vaccine
The Working Group will be asked to review the evidence with respect to the following questions/issues and to propose recommendations for review by SAGE. This will lead to the publication of a WHO vaccine position paper on the use of hepatitis E. The target date of the publication of the position paper is early 2015. Details here:
http://www.who.int/immunization/sage/nominations_working_group_hep_E_aug2013/en/index.html

American Journal of Bioethics – Special Issue on Immunization Mandates and HCP

The American Journal of Bioethics
Volume 13, Issue 9, 2013
http://www.tandfonline.com/toc/uajb20/current#.Uhk8Az_hflY

Editorial
Vaccine Mandates Are Justifiable Because We Are All in This Together
John D. Lantos & Mary Anne Jackson
pages 1-2
http://www.tandfonline.com/doi/full/10.1080/15265161.2013.815021#.Uhk8pj_hflY
No abstract

An Ethical Analysis of Mandatory Influenza Vaccination of Health Care Personnel: Implementing Fairly and Balancing Benefits and Burdens
Armand H. Matheny Antommaria
pages 30-37
DOI:10.1080/15265161.2013.814731
Published online: 16 Aug 2013
Abstract
Health care institutions have paid increasing attention to preventing nosocomial transmission of influenza through vaccination of health care personnel. While multifaceted voluntary interventions have increased vaccination rates, proponents of mandatory programs contend the rates remain unacceptably low. Conventional bioethical analyses of mandatory programs are inadequate; they fail to account for the obligations of nonprofessional personnel or to justify the weights assigned to different ethical principles. Using an ethics framework for public health permits a fuller analysis. The framework’s focus on fairness accentuates the potential differences between the risk of transmitting infection and employment status, and the need to equitably evaluate exemptions. The framework’s emphasis on balancing benefits and burdens highlights the need to justify a specific goal and questions the need to exclude all nonmedical exemptions. While mandatory vaccination programs are justifiable, greater attention should be paid to their implementation.

The Case for Mandatory Flu Vaccination of Children
Ben Bambery, Michael Selgelid, Hannah Maslen, Andrew J. Pollard & Julian Savulescu
pages 38-40
DOI:10.1080/15265161.2013.813602
Published online: 16 Aug 2013
No abstract

Guidance From Vaccination Jurisprudence
Michael R. Ulrich
pages 40-42
DOI:10.1080/15265161.2013.813608
Published online: 16 Aug 2013
No abstract

Before the Mandate: Cultivating an Organizational Culture of Trust and Integrity
Joshua E. Perry
pages 42-44
DOI:10.1080/15265161.2013.813600
Published online: 16 Aug 2013
No abstract

Exemptions From Influenza Vaccinations for Health Care Personnel Based on Self or Identity Issues: Are They Justified?
David Trafimow
pages 44-46
DOI:10.1080/15265161.2013.813598
Published online: 16 Aug 2013
No abstract

Evidence and Ethics in Mandatory Vaccination Policies
Jason L. Schwartz
pages 46-48
DOI:10.1080/15265161.2013.815023
Published online: 16 Aug 2013
No abstract

Mandatory Influenza Vaccination: How Far to Go and Whom to Target Without Evidence?
Jean-Christophe Bélisle Pipon & Marjolaine Frenette
pages 48-50
DOI:10.1080/15265161.2013.813607
Published online: 16 Aug 2013
No abstract

Professional Solidarity: The Case of Influenza Immunization
Mariëtte van den Hoven & Marcel Verweij
pages 51-52
DOI:10.1080/15265161.2013.813606
Published online: 16 Aug 2013
No abstract

How the Weight of the Ethical Arguments Depends on the Empirical “Facts”
Georg Marckmann, Anna M. Sanktjohanser & Sabine Wicker
pages 53-55
DOI:10.1080/15265161.2013.813605
Published online: 16 Aug 2013
No abstract

Applying Kass’s Public Health Ethics Framework to Mandatory Health Care Worker Immunization: The Devil is in the Details
Saad B. Omer
pages 55-57
DOI:10.1080/15265161.2013.825122
Published online: 16 Aug 2013
No abstract

Middle East Respiratory Syndrome Coronavirus in Bats, Saudi Arabia

Emerging Infectious Diseases
Volume 19, Number 9—September 2013
http://www.cdc.gov/ncidod/EID/index.htm

Dispatch
Middle East Respiratory Syndrome Coronavirus in Bats, Saudi Arabia
Ziad A. Memish, Nischay Mishra, Kevin J. Olival, Shamsudeen F. Fagbo, Vishal Kapoor, Jonathan H. Epstein, Rafat AlHakeem, Abdulkareem Durosinloun, Mushabab Al Asmari, Ariful Islam, Amit Kapoor, Thom
http://wwwnc.cdc.gov/eid/article/19/11/13-1172_article.htm

Abstract
The source of human infection with Middle East respiratory syndrome coronavirus remains unknown. Molecular investigation indicated that bats in Saudi Arabia are infected with several alphacoronaviruses and betacoronaviruses. Virus from 1 bat showed 100% nucleotide identity to virus from the human index case-patient. Bats might play a role in human infection.

Protection by Face Masks against Influenza A(H1N1)pdm09 Virus on Trans-Pacific Passenger Aircraft,

Emerging Infectious Diseases
Volume 19, Number 9—September 2013
http://www.cdc.gov/ncidod/EID/index.htm

Research
Protection by Face Masks against Influenza A(H1N1)pdm09 Virus on Trans-Pacific Passenger Aircraft, 2009
Lijie Zhang1, Zhibin Peng1, Jianming Ou1, Guang Zeng1, Robert E. Fontaine, Mingbin Liu, Fuqiang Cui, Rongtao Hong, Hang Zhou, Yang Huai, Shuk-Kwan Chuang, Yiu-Hong Leung, Yunxia Feng, Yuan Luo, Tao Shen, Bao-Ping Zhu, Marc-Alain Widdowson, and Hongjie Yu
http://wwwnc.cdc.gov/eid/article/19/9/12-1765_article.htm

Abstract
In response to several influenza A(H1N1)pdm09 infections that developed in passengers after they traveled on the same 2 flights from New York, New York, USA, to Hong Kong, China, to Fuzhou, China, we assessed transmission of influenza A(H1N1)pdm09 virus on these flights. We defined a case of infection as onset of fever and respiratory symptoms and detection of virus by PCR in a passenger or crew member of either flight. Illness developed only in passengers who traveled on the New York to Hong Kong flight. We compared exposures of 9 case-passengers with those of 32 asymptomatic control-passengers. None of the 9 case-passengers, compared with 47% (15/32) of control-passengers, wore a face mask for the entire flight (odds ratio 0, 95% CI 0–0.71). The source case-passenger was not identified. Wearing a face mask was a protective factor against influenza infection. We recommend a more comprehensive intervention study to accurately estimate this effect

Investigation of an imported case of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection in Florence, Italy, May to June 2013

Eurosurveillance
Volume 18, Issue 34, 22 August 2013
http://www.eurosurveillance.org/Public/Articles/Archives.aspx?PublicationId=11678

Rapid communications
Investigation of an imported case of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection in Florence, Italy, May to June 2013
by S Puzelli, A Azzi, MG Santini, A Di Martino, M Facchini, MR Castrucci, M Meola, R Arvia, F Corcioli, F Pierucci, S Baretti, A Bartoloni, D Bartolozzi, M de Martino, L Galli, MG Pompa, G Rezza, E Balocchini, I Donatelli

Health technology assessments as a mechanism for increased value for money: recommendations to the global fund

Globalization and Health
[Accessed 24 August 2013]
http://www.globalizationandhealth.com/

Review
Health technology assessments as a mechanism for increased value for money: recommendations to the global fund
Teerawattananon Y, McQueston K, Glassman A, Yothasamut J and Myint CY Globalization and Health 2013, 9:35 (21 August 2013)

Abstract (provisional)
The Global Fund is experiencing increased pressure to optimize results and improve its impact per dollar spent. It is also in transition from a provider of emergency funding, to a long-term, sustainable financing mechanism. This paper assesses the efficacy of current Global Fund investment and examines how health technology assessments (HTAs) can be used to provide guidance on the relative priority of health interventions currently subsidized by the Global Fund. In addition, this paper identifies areas where the application of HTAs can exert the greatest impact and proposes ways in which this tool could be incorporated, as a routine component, into application, decision, implementation, and monitoring and evaluation processes. Finally, it addresses the challenges facing the Global Fund in realizing the full potential of HTAs.

Preparing routine health information systems for immediate health responses to disasters

Health Policy and Planning
Volume 28 Issue 5 August 2013
http://heapol.oxfordjournals.org/content/current

Preparing routine health information systems for immediate health responses to disasters
Eindra Aung1,* and Maxine Whittaker2
Accepted July 7, 2012.
[Free text] http://heapol.oxfordjournals.org/content/28/5/495.abstract

Abstract
During disaster times, we need specific information to rapidly plan a disaster response, especially in sudden-onset disasters. Due to the inadequate capacity of Routine Health Information Systems (RHIS), many developing countries face a lack of quality pre-disaster health-related data and efficient post-disaster data processes in the immediate aftermath of a disaster. Considering the significance of local capacity during the early stages of disaster response, RHIS at local, provincial/state and national levels need to be strengthened so that they provide relief personnel up-to-date information to plan, organize and monitor immediate relief activities. RHIS professionals should be aware of specific information needs in disaster response (according to the Sphere Project’s Humanitarian Minimum Standards) and requirements in data processes to fulfil those information needs. Preparing RHIS for disasters can be guided by key RHIS-strengthening frameworks; and disaster preparedness must be incorporated into countries’ RHIS. Mechanisms must be established in non-disaster times and maintained between RHIS and information systems of non-health sectors for exchanging disaster-related information and sharing technologies and cost.

From reaching every district to reaching every community: analysis and response to the challenge of equity in immunization in Cambodia

Health Policy and Planning
Volume 28 Issue 5 August 2013
http://heapol.oxfordjournals.org/content/current

From reaching every district to reaching every community: analysis and response to the challenge of equity in immunization in Cambodia
Sann Chan Soeung1, John Grundy2, Richard Duncan3,*, Rasoka Thor4 and Julian B Bilous5
Accepted July 11, 2012.

Abstract
Background   An international review of the Cambodian Expanded Programme on Immunization (EPI) in 2010 and other data show that despite immunization coverage increases and vaccine preventable diseases incidence reductions, inequities in access to immunization services exist. Utilizing immunization and health systems literature, analysis of global health databases and the EPI review findings, this paper examines the characteristics of immunization access and outcome inequities, and describes proposed longer-term strategic and operational responses to these problems.

Findings   The national programme has evolved from earlier central and provincial level planning to strengthening routine immunization coverage through the District level ‘Reaching Every District Strategy’. However, despite remarkable improvements, the review found over 20% of children surveyed were not fully immunized, primarily from communities where inequities of both access and impact persist. These inequities relate mainly to socio-economic exposures including wealth and education level, population mobility and ethnicity. To address these problems, a shift in strategic and operational response is proposed that will include (a) a re-focus of planning on facility level to detect disadvantaged communities, (b) establishment of monitoring systems to provide detailed information on community access and utilization, (c) development of communication strategies and health networks that enable providers to adjust service delivery according to the needs of vulnerable populations, and (d) securing financial, management and political commitment for ‘reaching every community’.

Conclusions   For Cambodia to achieve its immunization equity objectives and disease reduction goals, a shift of emphasis to health centre and community is needed. This approach will maximize the benefits of new vaccine introduction in the coming ‘Decade of Vaccines’, plus potentially extend the reach of other life-saving maternal and child health interventions to the socially disadvantaged, both in Cambodia and in other countries with a similar level of development.

Infectious disease risk from the Syrian conflict

International Journal of Infectious Diseases
Vol 17 | No. 9 | September 2013
http://www.ijidonline.com/current

Infectious disease risk from the Syrian conflict
Eskild Petersen, Susan Baekeland, Ziad A. Memish, Hakan Leblebicioglu
Received 3 June 2013; accepted 4 June 2013. published online 15 July 2013.
http://www.ijidonline.com/article/S1201-9712%2813%2900200-2/fulltext

Preview
The breakdown of health care in Syria under the present conflict has been highlighted in ProMED reports on the increasing risk of leishmaniasis and rabies. However, these reports merely reflect the dr…

The State of US Health, 1990-2010Burden of Diseases, Injuries, and Risk Fact

JAMA   
http://jama.jamanetwork.com/issue.aspx
August 14, 2013, Vol 310, No. 6

Original Investigation | August 14, 2013
The State of US Health, 1990-2010Burden of Diseases, Injuries, and Risk Factors
US Burden of Disease Collaborators; Christopher J. L. Murray, MD, DPhil, et al
http://jama.jamanetwork.com/article.aspx?articleid=1710486

ABSTRACT
Importance   Understanding the major health problems in the United States and how they are changing over time is critical for informing national health policy.

Objectives   To measure the burden of diseases, injuries, and leading risk factors in the United States from 1990 to 2010 and to compare these measurements with those of the 34 countries in the Organisation for Economic Co-operation and Development (OECD) countries.

Design   We used the systematic analysis of descriptive epidemiology of 291 diseases and injuries, 1160 sequelae of these diseases and injuries, and 67 risk factors or clusters of risk factors from 1990 to 2010 for 187 countries developed for the Global Burden of Disease 2010 Study to describe the health status of the United States and to compare US health outcomes with those of 34 OECD countries. Years of life lost due to premature mortality (YLLs) were computed by multiplying the number of deaths at each age by a reference life expectancy at that age. Years lived with disability (YLDs) were calculated by multiplying prevalence (based on systematic reviews) by the disability weight (based on population-based surveys) for each sequela; disability in this study refers to any short- or long-term loss of health. Disability-adjusted life-years (DALYs) were estimated as the sum of YLDs and YLLs. Deaths and DALYs related to risk factors were based on systematic reviews and meta-analyses of exposure data and relative risks for risk-outcome pairs. Healthy life expectancy (HALE) was used to summarize overall population health, accounting for both length of life and levels of ill health experienced at different ages.

Results   US life expectancy for both sexes combined increased from 75.2 years in 1990 to 78.2 years in 2010; during the same period, HALE increased from 65.8 years to 68.1 years. The diseases and injuries with the largest number of YLLs in 2010 were ischemic heart disease, lung cancer, stroke, chronic obstructive pulmonary disease, and road injury. Age-standardized YLL rates increased for Alzheimer disease, drug use disorders, chronic kidney disease, kidney cancer, and falls. The diseases with the largest number of YLDs in 2010 were low back pain, major depressive disorder, other musculoskeletal disorders, neck pain, and anxiety disorders. As the US population has aged, YLDs have comprised a larger share of DALYs than have YLLs. The leading risk factors related to DALYs were dietary risks, tobacco smoking, high body mass index, high blood pressure, high fasting plasma glucose, physical inactivity, and alcohol use. Among 34 OECD countries between 1990 and 2010, the US rank for the age-standardized death rate changed from 18th to 27th, for the age-standardized YLL rate from 23rd to 28th, for the age-standardized YLD rate from 5th to 6th, for life expectancy at birth from 20th to 27th, and for HALE from 14th to 26th.

Conclusions and Relevance   From 1990 to 2010, the United States made substantial progress in improving health. Life expectancy at birth and HALE increased, all-cause death rates at all ages decreased, and age-specific rates of years lived with disability remained stable. However, morbidity and chronic disability now account for nearly half of the US health burden, and improvements in population health in the United States have not kept pace with advances in population health in other wealthy nations.

Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk

The Lancet  
http://www.thelancet.com/journals/lancet/issue/current
Aug 24, 2013  Volume 382  Number 9893  p659 – 742

Comment
Assessing the pandemic potential of MERS-CoV
Chris T Bauch, Tamer Oraby
Preview |
The emergence in 2012 of a new disease-causing coronavirus has generated substantial concern. As of June 26, 2013, Middle East respiratory syndrome coronavirus (MERS-CoV) had caused 77 laboratory-confirmed cases and 40 deaths.1 The virus is related to the severe acute respiratory syndrome coronavirus (SARS-CoV) that emerged in 2002–03. And, as SARS-CoV had during its prepandemic stage, MERS-CoV has probably been transmitted from an unknown animal host to human beings repeatedly in the past year.2,3 Cases of human-to-human transmission have also been documented in several countries.

Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk
Romulus Breban PhD a, Julien Riou a, Prof Arnaud Fontanet PhD a b
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2961492-0/abstract

Summary
Background
The new Middle East respiratory syndrome coronavirus (MERS-CoV) infection shares many clinical, epidemiological, and virological similarities with that of severe acute respiratory syndrome (SARS)-CoV. We aimed to estimate virus transmissibility and the epidemic potential of MERS-CoV, and to compare the results with similar findings obtained for prepandemic SARS.

Methods
We retrieved data for MERS-CoV clusters from the WHO summary and subsequent reports, and published descriptions of cases, and took into account 55 of the 64 laboratory-confirmed cases of MERS-CoV reported as of June 21, 2013, excluding cases notified in the previous 2 weeks. To assess the interhuman transmissibility of MERS-CoV, we used Bayesian analysis to estimate the basic reproduction number (R0) and compared it to that of prepandemic SARS. We considered two scenarios, depending on the interpretation of the MERS-CoV cluster-size data.

Results
With our most pessimistic scenario (scenario 2), we estimated MERS-CoV R0 to be 0·69 (95% CI 0·50—0·92); by contrast, the R0 for prepandemic SARS-CoV was 0·80 (0·54—1·13). Our optimistic scenario (scenario 1) yielded a MERS-CoV R0 of 0·60 (0·42—0·80). Because of recent implementation of effective contact tracing and isolation procedures, further MERS-CoV transmission data might no longer describe an entire cluster, but only secondary infections directly caused by the index patient. Hence, we calculated that, under scenario 2, eight or more secondary infections caused by the next index patient would translate into a 5% or higher chance that the revised MERS-CoV R0 would exceed 1—ie, that MERS-CoV might have pandemic potential.

Interpretation
Our analysis suggests that MERS-CoV does not yet have pandemic potential. We recommend enhanced surveillance, active contact tracing, and vigorous searches for the MERS-CoV animal hosts and transmission routes to human beings.

Funding
Agence Nationale de la Recherche (Labex Integrative Biology of Emerging Infectious Diseases), and the European Community’s Seventh Framework Programme project PREDEMICS.

Performance-based financing at the Global Fund to Fight AIDS, Tuberculosis and Malaria: an analysis of grant ratings and funding, 2003–12

The Lancet Global Health
Sep 2013  Volume 1  Number 3  e116 – 168
http://www.thelancet.com/journals/langlo/issue/current

Performance-based financing at the Global Fund to Fight AIDS, Tuberculosis and Malaria: an analysis of grant ratings and funding, 2003–12
Victoria Y Fan, Denizhan Duran, Rachel Silverman, Amanda Glassman
http://www.thelancet.com/journals/langlo/article/PIIS2214-109X%2813%2970017-2/abstract

Summary
Background
Performance-based financing can be used by global health funding agencies to improve programme performance and thus value for money. The Global Fund to Fight AIDS, Tuberculosis and Malaria was one of the first global-health funders to deploy a performance-based financing system. However, its complex, multistep system for calculating and paying on grant ratings has several components that are subjective and discretionary. We aimed to test the association between grant ratings and disbursements, an indication of the extent to which incentives for performance are transmitted to grant recipients.

Methods
We obtained publicly available data for 508 Global Fund grants from 2003 to 2012 with performance ratings and corresponding disbursements, merged with other datasets that contained data for relevant country characteristics. We used regression analysis to identify predictors of grant disbursements in phase 2 (typically the latter 3 of 5 years of a grant), using two dependent variables: whether a grant had any phase-2 disbursements, and the phase-2 disbursement amount. In a separate analysis, we also investigated the predictors of grant performance ratings.

Findings
Grant performance rating in phase 1 was positively associated with having any disbursements in phase 2, but no association was seen between phase-1 ratings and phase-2 disbursement amounts. Furthermore, performance ratings are not replicable by external observers, both because subjective and discretionary decisions are made in the generation of performance measures and because the underlying data are not available.

Interpretation
The Global Fund’s present performance-based funding system does not adequately convey incentives for performance to recipients, and the organisation should redesign this system to explicitly link a portion of the funds to a simple performance measure in health coverage or outcomes, measured independently and robustly.

Funding
Bill & Melinda Gates Foundation

Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study

The Lancet Infectious Diseases
Sep 2013  Volume 13  Number 9   p725 – 822
http://www.thelancet.com/journals/laninf/issue/current

Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study
Jeffrey C Kwong, Priya P Vasa, Michael A Campitelli, Steven Hawken, Kumanan Wilson, Laura C Rosella, Therese A Stukel, Natasha S Crowcroft, Allison J McGeer, Lorne Zinman, Shelley L Deeks
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2813%2970104-X/abstract

Summary
Background
The possible risk of Guillain-Barré syndrome from influenza vaccines remains a potential obstacle to achieving high vaccination coverage. However, influenza infection might also be associated with Guillain-Barré syndrome. We aimed to assess the risk of Guillain-Barré syndrome after seasonal influenza vaccination and after influenza-coded health-care encounters.

Methods
We used the self-controlled risk interval design and linked universal health-care system databases from Ontario, Canada, with data obtained between 1993 and 2011. We used physician billing claims for influenza vaccination and influenza-coded health-care encounters to ascertain exposures. Using fixed-effects conditional Poisson regression, we estimated the relative incidence of hospitalisation for primary-coded Guillain-Barré syndrome during the risk interval compared with the control interval.

Findings
We identified 2831 incident admissions for Guillain-Barré syndrome; 330 received an influenza vaccine and 109 had an influenza-coded health-care encounter within 42 weeks before hospitalisation. The risk of Guillain-Barré syndrome within 6 weeks of vaccination was 52% higher than in the control interval of 9—42 weeks (relative incidence 1·52; 95% CI 1·17—1·99), with the greatest risk during weeks 2—4 after vaccination. The risk of Guillain-Barré syndrome within 6 weeks of an influenza-coded health-care encounter was greater than for vaccination (15·81; 10·28—24·32). The attributable risks were 1·03 Guillain-Barré syndrome admissions per million vaccinations, compared with 17·2 Guillain-Barré syndrome admissions per million influenza-coded health-care encounters.

Interpretation
The relative and attributable risks of Guillain-Barré syndrome after seasonal influenza vaccination are lower than those after influenza illness. Patients considering immunisation should be fully informed of the risks of Guillain-Barré syndrome from both influenza vaccines and influenza illness.

Funding
Canadian Institutes of Health Research.

The hidden threat that could prevent Polio’s global eradication [excreters]

Nature | Scientific American

The hidden threat that could prevent Polio’s global eradication
Polio could soon be wiped out—but only if scientists can track down the last carriers
Helen Branswell
14 August 2013
Extract
Global eradication of polio has been the ultimate game of Whack-a-Mole for the past decade; when it seems the virus has been beaten into submission in a final refuge, up it pops in a new region. Now, as vanquishing polio worldwide appears again within reach, another insidious threat may be in store from infection sources hidden in plain view.

Polio’s latest redoubts are “chronic excreters,” people with compromised immune systems who, having swallowed weakened polioviruses in an oral vaccine as children, generate and shed live viruses from their intestines and upper respiratory tracts for years. Healthy children react to the vaccine by developing antibodies that shut down viral replication, thus gaining immunity to infection. But chronic excreters cannot quite complete that process and instead churn out a steady supply of viruses. The oral vaccine’s weakened viruses can mutate and regain wild polio’s hallmark ability to paralyze the people it infects. After coming into wider awareness in the mid-1990s, the condition shocked researchers…

Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning

Nature Reviews Immunology
September 2013 Vol 13 No 9
http://www.nature.com/nri/journal/v13/n9/index.html

Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
Peter D. Kwong, John R. Mascola & Gary J. Nabel
http://www.nature.com/nri/journal/v13/n9/abs/nri3516.html

Abstract
The field of HIV-1 vaccine research has seen a renaissance with the identification of antibodies that neutralize most circulating HIV-1 strains. An understanding of the structural mode of target recognition that these antibodies use and the immune pathways that lead to their development is emerging. This knowledge has provided fundamental insights into the pathways that elicit broadly neutralizing antibodies and provides a foundation for active and passive immunization strategies to prevent HIV-1 infection.

Knowledge, Attitude, Practice and Barriers on Vaccination against Human Papillomavirus Infection: A Cross-Sectional Study among Primary Care Physicians in Hong Kong

PLoS One
[Accessed 24 August 2013]
http://www.plosone.org/

Knowledge, Attitude, Practice and Barriers on Vaccination against Human Papillomavirus Infection: A Cross-Sectional Study among Primary Care Physicians in Hong Kong
Martin C. S. Wong, Albert Lee, Karry L. K. Ngai, Josette C. Y. Chor, Paul K. S. Chan
Research Article | published 21 Aug 2013 | PLOS ONE 10.1371/journal.pone.0071827

Abstract
This study explored the knowledge, attitude, practice and barriers to prescribe human papillomavirus (HPV) vaccines among private primary care physicians in Hong Kong. A self-administered questionnaire survey was conducted by sending letters to doctors who had joined a vaccination program for school girls. From 720 surveys sent, 444 (61.7%) completed questionnaires were returned and analyzed. For knowledge, few responded to questions accurately on the prevalence of cervical HPV (27.9%) and genital wart infection (13.1%) among sexually active young women in Hong Kong, and only 44.4% correctly answered the percentage of cervical cancers caused by HPV. For attitude, most agreed that HPV vaccination should be fully paid by the Government (68.3%) as an important public health strategy. Vaccination against HPV was perceived as more important than those for genital herpes (52.2%) and Chlamydia (50.1%) for adolescent health, and the majority selected adolescents aged 12–14 years as the ideal group for vaccination. Gardasil® (30.9%) and Cervarix® (28.0%) were almost equally preferred. For practice, the factors influencing the choice of vaccine included strength of vaccine protection (61.1%), long-lasting immunity (56.8%) and good antibody response (55.6%). The most significant barriers to prescribe HPV vaccines consisted of parental refusal due to safety concerns (48.2%), and their practice of advising vaccination was mostly affected by local Governmental recommendations (78.7%). A substantial proportion of physicians had recommended HPV vaccines for their female clients/patients aged 18–26 years for protection of cervical cancer (83.8%) or both cervical cancer and genital warts (85.5%). The knowledge on HPV infection was low among physicians in Hong Kong. Prescription of HPV vaccine was hindered by the perceived parental concerns and was mostly relied on Governmental recommendations. Educational initiatives should be targeted towards both physicians and parents, and the Government should consider full subsidy to enhance vaccine uptake rate.

The Expected Number of Background Disease Events during Mass Immunization in China

PLoS One
[Accessed 24 August 2013]
http://www.plosone.org/

The Expected Number of Background Disease Events during Mass Immunization in China
YouXin Wang, LiJuan Wu, XinWei Yu, FeiFei Zhao, Alyce Russell, ManShu Song, Wei Wang
Research Article | published 20 Aug 2013 | PLOS ONE 10.1371/journal.pone.0071818

Abstract
It is critical to distinguish events that are temporarily associated with, but not caused by, vaccination from those caused by vaccination during mass immunization. We performed a literature search in China National Knowledge Infrastructure and Pubmed databases. The number of coincident events was calculated based on its incidence rate and periods after receipt of a dose of hypothesized vaccine. We included background incidences of Guillain-Barré syndrome, anaphylaxis, seizure, sudden adult death syndrome, sudden cardiac death, spontaneous abortion, and preterm labour or delivery. In a cohort of 10 million individuals, 7.71 cases of Guillain-Barré syndrome would be expected to occur within six weeks of vaccination as coincident background cases. Even for rare events, a large number of events can be expected in a short period because of the large population targeted for immunization. These findings may encourage health authorities to screen the safety of vaccines against unpredictable pathogens.

Vaccine Perceptions Among Oregon Health Care Providers

Qualitative Health Research
September 2013; 23 (9)
http://qhr.sagepub.com/content/current

Vaccine Perceptions Among Oregon Health Care Providers
Sandra J. Bean1, Joseph A. Catania1
1Oregon State University, Corvallis, Oregon, USA
Sandra J. Bean, Oregon State University, School of Social and Behavioral Health Sciences, 322 Milam Hall, Corvallis, OR 97333-5102, USA.
http://qhr.sagepub.com/content/23/9/1251.abstract

Abstract
Health care providers exert a significant influence on parental pediatric vaccination decisions. We conducted hour-long interviews with traditional and alternative health care providers in which we explored a range of associations between vaccination perceptions and practice. A key finding was that the Health Belief Model constructs of perceived susceptibility to and severity of either an illness or an adverse vaccine event partially explained health care provider (HCP) beliefs about the risks or benefits of vaccination, especially among alternative care providers. Low or high perceived susceptibility to a vaccine-preventable disease (VPD) or of the severity of a given VPD affects whether an HCP will promote or oppose pediatric vaccination recommendations. Beyond these perceptions, health and vaccination beliefs are affected by the contextual factors of personal experience, group norms, immunology beliefs, and beliefs about industry and government. Building powerful affective heuristics might be critical to balancing the forces that defeat good public health practices.

National Security and Pandemics

UN Chronicle
Vol 1, No.2, 2013
http://www.un.org/wcm/content/site/chronicle/home/archive/issues2013/security

National Security and Pandemics
By Sara E. Davies18.07.2013
Pandemics are for the most part disease outbreaks that become widespread as a result of the spread of human-to-human infection. Beyond the debilitating, sometimes fatal, consequences for those directly affected, pandemics have a range of negative social, economic and political consequences

Research on vaccines during pregnancy

Vaccine
http://www.sciencedirect.com/science/journal/0264410X
Volume 31, Issue 40, Pages 4261-4464 (13 September 2013)

Research on vaccines during pregnancy: Reference values for vital signs and laboratory assessments
Original Research Article
Pages 4264-4273
Jeanne S. Sheffield, Flor M. Munoz, Richard H. Beigi, Sonja A. Rasmussen, Kathryn M. Edwards, Jennifer S. Read, R. Phillips Heine, Kevin A. Ault, Geeta K. Swamy, Indira Jevaji, Catherine Y. Spong, Kimberly B. Fortner, Shital M. Patel, Mirjana Nesin

Highlights
:: A toxicity grading scale is defined for adverse event reporting in pregnancy.
:: Vital sign changes in pregnancy are discussed and toxicity grading developed for each trimester.
:: Normal laboratory values are listed and a toxicity grade is assigned based on value and trimester of pregnancy.

Abstract
The Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes of Health organized a series of conferences, “Enrolling Pregnant Women in Clinical Trials of Vaccines and Therapeutics”, to discuss enrollment and safety assessments of pregnant women in clinical trials of vaccines. Experts in obstetrics, maternal–fetal medicine, infectious diseases, pediatrics, neonatology, genetics, vaccinology and clinical trial design were charged with identifying normal ranges for vital signs and laboratory assessments in pregnancy. A grading system for adverse events was then developed

Research on vaccines during pregnancy: Protocol design and assessment of safety
Original Research Article
Pages 4274-4279
Flor M. Munoz, Jeanne S. Sheffield, Richard H. Beigi, Jennifer S. Read, Geeta K. Swamy, Indira Jevaji, Sonja A. Rasmussen, Kathryn M. Edwards, Kimberly B. Fortner, Shital M. Patel, Catherine Y. Spong, Kevin Ault, R. Philips Heine, Mirjana Nesin

Abstract
The Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes of Health organized a series of conferences, entitled “Enrolling Pregnant Women in Clinical Trials of Vaccines and Therapeutics”, to discuss study design and the assessment of safety in clinical trials conducted in pregnant women. A panel of experts was charged with developing guiding principles for the design of clinical trials and the assessment of safety of vaccines during pregnancy. Definitions and a grading system to evaluate local and systemic reactogenicity, adverse events, and other events associated with pregnancy and delivery were developed. The purpose of this report is to provide investigators interested in vaccine research in pregnancy with a basic set of tools to design and implement maternal immunization studies which may be conducted more efficiently using consistent definitions and grading of adverse events to allow the comparison of safety reports from different trials. These guidelines and safety assessment tools may be modified to meet the needs of each particular protocol based on evidence collected as investigators use them in clinical trials in different settings and share their findings and expertise.

A systematic review of interventions for reducing parental vaccine refusal and vaccine hesitancy

Vaccine
http://www.sciencedirect.com/science/journal/0264410X
Volume 31, Issue 40, Pages 4261-4464 (13 September 2013)

A systematic review of interventions for reducing parental vaccine refusal and vaccine hesitancy
Review Article
Pages 4293-4304
Alina Sadaf, Jennifer L. Richards, Jason Glanz, Daniel A. Salmon, Saad B. Omer

Abstract
Unvaccinated individuals pose a public health threat to communities. Research has identified many factors associated with parental vaccine refusal and hesitancy toward childhood and adolescent immunizations. However, data on the effectiveness of interventions to address parental refusal are limited. We conducted a systematic review of four online databases to identify interventional studies.

We used criteria recommended by the WHO’s Strategic Advisory Group of Experts on immunization (SAGE) for the quality assessment of studies. Intervention categories and outcomes were evaluated for each body of evidence and confidence in overall estimates of effect was determined. There is limited evidence to guide implementation of effective strategies to deal with the emerging threat of parental vaccine refusal. There is a need for appropriately designed, executed and evaluated intervention studies to address this gap in knowledge.

International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines

Vaccine
http://www.sciencedirect.com/science/journal/0264410X
Volume 31, Issue 40, Pages 4261-4464 (13 September 2013)

International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines
Original Research Article
Pages 4448-4458
Caitlin N. Dodd, Silvana A. Romio, Steven Black, Claudia Vellozzi, Nick Andrews, Miriam Sturkenboom, Patrick Zuber, Wei Hua, Jan Bonhoeffer, Jim Buttery, Nigel Crawford, Genevieve Deceuninck, Corinne de Vries, Philippe De Wals, M. Victoria Gutierrez- Gimeno, Harald Heijbel, Hayley Hughes, Kwan Hur, Anders Hviid, Jeffrey Kelman, et al

Abstract
Background
The global spread of the 2009 novel pandemic influenza A (H1N1) virus led to the accelerated production and distribution of monovalent 2009 Influenza A (H1N1) vaccines (pH1N1). This pandemic provided the opportunity to evaluate the risk of Guillain–Barré syndrome (GBS), which has been an influenza vaccine safety concern since the swine flu pandemic of 1976, using a common protocol among high and middle-income countries. The primary objective of this project was to demonstrate the feasibility and utility of global collaboration in the assessment of vaccine safety, including countries both with and without an established infrastructure for vaccine active safety surveillance. A second objective, included a priori, was to assess the risk of GBS following pH1N1 vaccination.

Methods
The primary analysis used the self-controlled case series (SCCS) design to estimate the relative incidence (RI) of GBS in the 42 days following vaccination with pH1N1 vaccine in a pooled analysis across databases and in analysis using a meta-analytic approach.

Results
We found a relative incidence of GBS of 2.42 (95% CI 1.58–3.72) in the 42 days following exposure to pH1N1 vaccine in analysis of pooled data and 2.09 (95% CI 1.28–3.42) using the meta-analytic approach.

Conclusions
This study demonstrates that international collaboration to evaluate serious outcomes using a common protocol is feasible. The significance and consistency of our findings support a conclusion of an association between 2009 H1N1 vaccination and GBS. Given the rarity of the event the relative incidence found does not provide evidence in contradiction to international recommendations for the continued use of influenza vaccines.

Review of recent literature on microneedle vaccine delivery technologies

Vaccine: Development and Therapy
(Accessed 24 August 2013)
http://www.dovepress.com/vaccine-development-and-therapy-journal

Review of recent literature on microneedle vaccine delivery technologies
Vrdoljak A
Abstract:
Microneedles (MNs) have been developed as medical devices for enhanced and painless transdermal drug and vaccine delivery. MN-based vaccine application, unlike conventional intramuscular or subcutaneous application using hypodermic needles, delivers vaccine directly into skin, which is known to be an immunologically much more relevant vaccination site than underlying tissue. Vaccination using MN devices targets the skin’s rich immune system, leading to better utilization of the antigen and resulting in superior immune response, often achieved using a lower vaccine dose than required by conventional delivery routes. However, despite the number of advantages and nearly four decades of research, the number of licensed MN-based vaccines remains limited to date. Nevertheless, it is to be expected that on the back of a number of recently developed scalable and robust MN-fabrication methods, more intensive translation into clinical practice will follow. Here, we review the current status and trends in research of MN-related vaccine delivery platforms, focusing on the most promising approaches and clinically relevant applications.

Potential Cost-Effectiveness of Pneumococcal Conjugate Vaccine (PCV) in Turkey

Value in Health                  
Vol 16 | No. 5 | July-August 2013 | Pages 699-906
http://www.valueinhealthjournal.com/current

Potential Cost-Effectiveness of Pneumococcal Conjugate Vaccine (PCV) in Turkey
Özden Türel, MD, Adnan Kisa, MSPH, PhD, E. David G. McIntosh, MBBS, MPH, LLM, PhD, ,
Mustafa Bakir, MD
http://www.valueinhealthjournal.com/article/S1098-3015%2813%2901810-X/abstract

ABSTRACT 
Background
Pneumococcal infection is an important and preventable cause of morbidity and mortality. The Turkish government introduced 7-valent pneumococcal conjugate vaccine (PCV) into the national immunization program in 2009. This suggests that replacing 7-valent PCV with a higher-valent version could at least maintain “standard of care” if not improve it, and that it could be affordable.

Objectives and Methods
The aim of this analysis was to assess the potential direct cost-effectiveness of 13-valent PCV in Turkey, a country with a birth cohort of 1.4 million, against a “no vaccine” state, against the default 7-valent PCV state, and against a 10-valent PCV state, using a published cohort model with a 5-year horizon.

Results and Conclusions
The cost per life-year gained is below the 1 × per-capita gross domestic product threshold across large changes in key input parameters, indicating that the model is stable and suggesting that any PCV would be very cost-effective in a Turkish national pediatric immunization schedule.

From Google Scholar+ [to 24 October 2013]

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

Study on the Performance of Cool Storage Material for Vaccine Transportation
B Liu, TH Zou, QD Hong, XY Song, CH Li – Advanced Materials Research, 2013
Abstract. It is introduced about the characteristics, structure and application of refrigerator for vaccine transportation. From the test of thermophysical properties of cool storage material in cold closet using for vaccine transportation and the insulation performance of cold closet …

[PDF] Poliovirus vaccination options for achieving eradication and securing the endgame
SGF Wassilak, RW Sutter, JD Wenger, WA Orenstein – Current Opinion in Virology, 2013
… The GPEI Strategic Plan 2013-18 includes plans for a global switch from tOPV to bOPV for routine immunization around 2016, provided prerequisites are met, including elimination of persistent cVDPV2 transmission in Nigeria and Somalia [23,24 ]. …

Arab revolutions: Ignoring a potential catastrophe (infectious and tropical diseases)

Al Jazeera
http://www.aljazeera.com/Services/Search/?q=vaccine
Accessed 24 August 2013

Arab revolutions: Ignoring a potential catastrophe (infectious and tropical diseases)
Peter Hotez
http://www.aljazeera.com/indepth/opinion/2013/08/2013815123611973409.html

Excerpt
Recent conflicts in Egypt, Iraq, Libya, Pakistan, Syria, Tunisia, Yemen, and elsewhere in the Middle East may have sufficiently destabilised national and international public health control measures to a point where several tropical diseases have either emerged and are sickening large populations in the region.
The most dramatic example is currently happening in Syria, where cutaneous leishmaniasis, a disfiguring parasitic skin disease transmitted by sandflies and also known as “Aleppo Evil”, is now affecting tens of thousands of innocent civilians both within the country and among refugees fleeing across the border to Lebanon or Turkey. But this disease is also flourishing in Afghanistan, Algeria, and Iraq where breakdowns in public health have allowed sandflies to breed and transmit disease.

Several mosquito-transmitted virus infections have also become important public health problems in the region. According to recent estimates 6 million cases of dengue fever occurred in Egypt in 2010 – more than 7 percent of that country’s population, while almost 14 million cases occurred that year in Pakistan. Dengue has also emerged in Saudi Arabia, Syria, and Yemen, while in both Saudi Arabia and Yemen, Rift valley fever has also appeared – the first time this mosquito-transmitted viral infection has been seen outside of Africa. There is concern that such viral infections could affect pilgrims entering Saudi Arabia during the Hajj this coming fall, as could the new MERS coronavirus, or the recently discovered Alkhurma hemorrhagic virus.  Both viruses were first discovered in Saudi Arabia…

Labor: families to lose tax benefit for failing to vaccinate children [Australia]

The Guardian
http://www.guardiannews.com/
Accessed 24 August 2013

Labor: families to lose tax benefit for failing to vaccinate children
Kevin Rudd says ‘hardline’ policy is aimed at getting immunisation rates as close to 100% as possible
18 August 2013  http://www.theguardian.com/world/2013/aug/18/labor-tax-benefit-vaccinate-children

Families who do not vaccinate their children will lose a tax supplement of $726 because other parents are worried about whether their children are safe at school from diseases such as whooping cough and measles, according to the prime minister, Kevin Rudd.

“That’s a hardline decision,” Rudd said. “I want to build an Australia where every mum and dad can feel safe and confident that when their kids go to school that practically every kid in that school is going to be immunised.”

Rudd released details of changes to its vaccination policy, which cuts out the Family Tax Benefit A annual supplement, currently worth $726 per child, for otherwise eligible parents who register as “conscientious objectors”.

“One of the great barbecue stoppers in the community across Australia is immunisation and [parents worry] whether their kids are perfectly safe at school – they have a concern and anxiety,” Rudd said.

The prime minister said although increased immunisation rates amongst five-year-olds had increased from 83% to 90% during Labor’s term in office, the aim was close to 100%.

Vaccinations cover childhood diseases such as polio, measles, whooping cough and rubella.

Although government policy requires all children to be vaccinated to enter school, parents who refused to vaccinate their children could previously claim exemptions for religious, medical or ideological reasons if they provided a statement of reasoning.

Under the policy change, “conscientious objectors” will no longer be eligible to claim the FTBA supplement if Labor is returned to office. Exemptions will still be allowed for religious and medical reasons.

Africa and Pakistan Face Polio Outbreaks, in Blow to Global Fight

New York Times
http://www.nytimes.com/
Accessed 24 August 2013

Africa and Pakistan Face Polio Outbreaks, in Blow to Global Fight
http://www.nytimes.com/2013/08/23/health/polio-outbreaks-seen-on-two-continents.html?_r=0
By DONALD G. McNEIL Jr.
Published: August 22, 2013
Excerpt
The global effort to eradicate polio, a disease that has been on the brink of extinction for years, is facing serious setbacks on two continents. The virus is surging in Somalia and the Horn of Africa, which had been largely free of cases for several years. And a new outbreak has begun in a part of Pakistan that a warlord declared off limits to vaccinators 14 months ago…

Vaccines: The Week in Review 10 August 2013

NOTICE: Vaccines: The Week in Review will resume publication on 24 August 2013 following duty travel by the editor.

.

Vaccines: The Week in Review is a weekly digest — summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated “29 June 2013″
.
Email Summary: Vaccines: The Week in Review is published as a single email summary, scheduled for release each Saturday eveningbefore midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.
.
pdf version: A pdf of the current issues is available here: Vaccines_The Week in Review_10 August 2013
.
Twitter: Readers can also follow developments on twitter: @vaxethicspolicy.
.
Links: We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.
.
Support: If you would like to join the growing list of individuals who support this service and its contribution to their roles in public health, clinical practice, government, IGOs/NGOs, research, industry and academia, please visit this page at The Wistar Institute, our co-founder and fiduciary. Thank you…
.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy
a program of the
– Division of Medical Ethics, NYU Medical School
– The Wistar Institute Vaccine Center
– Children’s Hospital of Philadelphia Vaccine Education Center
Associate Faculty, Division of Medical Ethics, NYU Medical School

UNICEF receives emergency contribution of US$1.3 million from Japan for Somalia polio campiagn

UNICEF said it received an emergency contribution of US$1.3 million from the Government of Japan “to procure and distribute urgently needed polio vaccines for children in Somalia.” Sikander Khan, UNICEF Somalia Representative, commented, “Lack of access to routine immunization in Somalia has created the largest known reservoir of unvaccinated children in a single geographic area in the world. The total number of Somali children who had never been vaccinated between 2008 and 2012 was estimated to reach a million. The poliovirus in such a large reservoir has the potential to result in a catastrophic outbreak, the likes of which are beginning to be seen and as such constitutes an international emergency.” Currently, Somalia has the second lowest coverage of polio vaccination through routine immunization in the world at 47 per cent after Equatorial Guinea. The funds will cover more than 5 million doses of oral polio vaccines for two rounds of Supplementary Immunization Activities for November and December.

http://www.unicef.org/media/media_70084.html

GPEI Update: Polio this week – As of 7 August 2013 — Israel Extend Polio Vaccnation Campaign

Update: Polio this week – As of 7 August 2013
Global Polio Eradication Initiative
Full report: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx
[Editor’s extract and bolded text]

:: Following confirmation of 24 new cases in the Horn of Africa last week, five more cases are confirmed this week, all from Somalia. See ‘Horn of Africa’ section for more.
:: In Pakistan, Federally Administered Tribal Areas (FATA) remains the major poliovirus reservoir in the country. Virus transmission in FATA is threatening progress achieved elsewhere in the country and in neighbouring Afghanistan. An analysis of vaccination status of non-polio acute flaccid paralysis (AFP) cases suggests that more than half of children in FATA remain under-immunized, with as many as 40% never having received a single dose of oral polio vaccine (OPV). See ‘Pakistan’ section for more.
:: In Israel, a supplementary immunization activity (SIA) with OPV is being conducted this week, targeting 200,000 children aged two months to ten years in the southern part of the country. The move follows isolation of wild poliovirus type 1 (WPV1) from sewage samples collected from 20 sampling sites since February. No cases of paralytic polio have been reported. While Israel has high vaccination coverage with inactivated polio vaccine (IPV), the objective of the OPV SIA is to boost mucosal immunity levels to rapidly interrupt virus circulation.

Nigeria
:: Two new WPV1 cases were reported in the past week (from Kano state), bringing the total number of WPV1 cases for 2013 to 42. One of the newly-reported cases is the most recent WPV1 in the country, with onset of paralysis on 14 July…
:: Following a new risk-classification of Local Government Areas (LGAs), aimed at improving the delivery of resources to areas where they are most needed, tailored approaches are being implemented in LGAs where performance has stalled, LGAs where performance has decreased and LGAs where access to populations is compromised due to insecurity.
:: Across all areas, strengthened efforts are being made to track the direct engagement and oversight by LGA Chairpersons.
:: The engagement of communities, and traditional and religious leaders, is continuing to be fostered. The Volunteer Community Mobilizer Network continues to be expanded, and social data analysis is expected to provide further understanding for children being chronically missed.
:: Operational plans for insecure areas feature the introduction of Permanent Health Teams (PHTs), conducting wall fencing vaccinations around insecure areas, expanding transit vaccinations, implementing Short Interval Additional Dose (SIAD) campaigns and engaging non-traditional partners…

Pakistan
:: …One new cVPDV2 case was reported in the past week, bringing the total number of cVDPV2 cases for 2013 to six. It is the most recent cVDPV2 case in the country and had onset of paralysis on 30 June (from North Waziristan, FATA – the third cVDPV2 in North Waziristan).
:: Two new positive environmental samples (WPV1) were confirmed, collected in early July from Peshawar, Khyber Pakhtunkhwa (KP) and Hyderabad, Sindh. In total, 24 environmental samples have tested positive for WPV1 in 2013 from various sites across Pakistan, the bulk from Peshawar (10) and Hyderabad (6).
:: In addition to this latest cVDPV2 case, North Waziristan is also affected by WPV1. It is an area where immunization campaigns have been suspended by local leaders since last June. To minimize the risk of a major WPV1 and/or cVDPV2 outbreak in this area, it is critical that access to children is granted as quickly as possible. Immunization campaigns in neighbouring high-risk areas are being intensified, to further boost population immunity levels in those areas and minimize the risk of further spread.
:: FATA remains the major poliovirus reservoir in Pakistan, both due to WPV1 and cVDPV2. Khyber Agency is particularly affected, accounting for 13 of this year’s 22 WPV1 cases in the country. Of six cVDPV2 cases in the country this year, three are from North Waziristan.
:: According to vaccination status of non-polio AFP cases, more than half of children in FATA are under-immunized, with as many as 40% never having received a single dose….

Horn of Africa
::Five new WPV1 cases were reported in the past week (all from Somalia), bringing the total number of WPV1 cases in the region to 110 (100 from Somalia and ten from Kenya). The most recent WPV1 case in the region had onset of paralysis on 10 July (from Somalia).
:: Two of the newly-reported cases are from Lower Shabelle, areas of which are inaccessible due to insecurity. Special strategies continue to be implemented for these areas, including increased local-level access negotiations, immunizing older age groups and setting up vaccination posts at entry/exit points of inaccessible areas…

.
Israel Extends Polio Vaccination Campaign
JERUSALEM | Fri Aug 9, 2013 1:33pm EDT
(Reuters) – Israel will administer the active polio vaccine to children nationwide beginning on August 18, the Health Ministry said on Friday, stepping up an inoculation campaign currently limited to the south of the country.

The decision was made after the virus was detected in sewage treatment plants in Lod and Ramle, towns close to Israel’s central hub city of Tel Aviv, the ministry said in a statement.

It said it would call on parents of children born after January 2004 to bring them to publicly-funded clinics to receive oral drops of a weakened active virus vaccine between August 18 and 25.

A smaller-scale vaccination campaign has been under way since August 4 in the south, where the virus was discovered in sewage last month. The Health Ministry said 20 percent of children there had been inoculated since, and the number would increase to 50 percent within a week…
http://www.reuters.com/article/2013/08/09/us-israel-polio-idUSBRE9780UL20130809

Guest Column – AllAfrica: Response to Polio Outbreaks Shows Global Eradication Plan Is Working

AllAfrica – Guest Column
Africa: Response to Polio Outbreaks Shows Global Eradication Plan Is Working
By Helen Rees, 5 August 2013
http://allafrica.com/stories/201308052603.html?viewall=1

Just as we were seeing record-low cases of polio worldwide and coming closer than ever to eradication, 105 new cases of wild polio have been identified in Kenya and Somalia, raising new concerns about low coverage and inaccessible populations in that area. While the outbreaks are undoubtedly a setback, the Global Polio Eradication Initiative (GPEI) had anticipated that sporadic cases would occur in vulnerable settings during the final push for polio eradication, and it’s noteworthy that the situation has been met with one of the quickest and most effective emergency responses to date.

Although polio has been cornered in a handful of countries, the last vestiges of the disease will be the most difficult to stop. For example, political instability and insecurity in some areas –which in Nigeria and Pakistan culminated in the targeted murder of health care workers engaged in delivering services earlier this year — hinder access to at-risk children and can fuel the risk of outbreaks. Fortunately, containing outbreaks, such as those in the Horn of Africa, is a crucial part of the GPEI’s Polio Eradication and Endgame Strategic Plan 2013-2018.

Over the past 10 years, the GPEI has improved its outbreak response by systematically learning lessons from the more than 100 polio outbreaks that have occurred worldwide.

Since May of this year, 10 polio cases have been confirmed in Kenya and 95 in Somalia. A dozen vaccination campaigns have been conducted from May through July 24 across Somalia, Kenya, Ethiopia and Yemen that aimed to reach more than 17 million individuals, including adults in some areas. Additional campaigns will be executed in August.

The polio team is benefitting from the world’s most advanced surveillance system, which detects polio cases faster and more precisely. It helped health experts quickly identify the 105 cases in the Horn of Africa – the vast majority of which occurred prior to the outbreak response activities – and subsequently guided where vaccination gaps needed to be filled. We now expect to see a drastic drop in new cases post-response. Since 2010, all but one outbreak of wild polio virus was stopped within six months.

But responding to outbreaks is only one element of the GPEI’s multi-faceted eradication plan, which outlines a comprehensive series of steps all countries should take to achieve eradication by 2018. For example, to prevent outbreaks in the first place, it is essential to ensure strong immunization systems are in place and vaccination rates are high.

That is why the polio eradication plan includes significant resources for the rapid fortification of routine immunization systems. The plan commits at least half of GPEI field personnel’s time to work to achieve this by the end of 2014 in endemic and high-risk countries.

Strengthening immunization has the added benefit of helping the fight against other vaccine-preventable diseases, such as rotavirus and measles.

For example, in India, the polio programme introduced a system to identify, track and immunize every newborn child in areas of the country that were at high risk for polio. These efforts helped ensure vulnerable infants were included in the routine immunization system so they would receive polio vaccines as well as others that are critical.

The global plan to eradicate polio comes with one very important caveat: it must be funded up front.

The current outbreak is just the most recent example of the risk endemic polio anywhere poses to children and polio-free countries everywhere. In 2009, a polio outbreak in Tajikistan resulted in nearly 500 polio cases and cost U.S.$10 million to end. China and the western and central parts of Africa have also seen recent outbreaks.

A fully funded plan ensures that tradeoffs are not made in emergency situations by using a meticulous modeling process to budget for future outbreaks. Full funding also gives GPEI the flexibility to effectively respond to sudden outbreaks while continuing to prioritize its intensive    efforts to end transmission in the three endemic countries: Nigeria, Pakistan and Afghanistan.      Earlier this year I joined with more than 400 scientists and global health experts to state my confidence in the GPEI plan. I remain a strong supporter of the plan today.

Eradicating polio is a daunting challenge, but new knowledge and innovations are leading the way. Over the last two decades, the polio program has developed highly sophisticated strategies to access the most marginalized and hard-to-reach communities by improving overall health infrastructures and increasing community trust. Applying these lessons to routine health programs will pave the way for the delivery of measles and rubella vaccines, as well as new vaccines and other health interventions, to previously unreached children.

It’s a tall order to reduce costs and increase vaccine uptake – especially in communities that have low motivation to prevent diseases they do not even see and where fear and social disruption hamper progress – but this will be the challenge of the future.

The world has a plan to end polio. It’s working, and we must stand behind it.

Helen Rees OBE is the executive director of the Wits Reproductive Health and HIV Institute at the University of the Witwatersrand in South Africa and honorary professor at the Department of Clinical Research at the London School of Hygiene and Tropical Medicine. She is also the chair of the World Health Organization’s Strategic Advisory Group of Experts (SAGE) on Immunization. She serves on the GAVI Alliance Board and PPC and on the South African NITAG

MSF, GAVI issue statements on pneumococcal conjugate vaccines (PCV), volume pricing, refugee access

MSF and GAVI issued statements addressing a new immunization initiative involving pneumococcal conjugate vaccines (PCV) for children in the Yida refugee camp in South Sudan and the larger context of pricing and availability of vaccines to the NGO community linked to GAVI purchasing volumes, current agreements with manufacturers, and resultant pricing for specific vaccines.

The MSF release of 8 August 2013 notes in part:
Global Vaccination Community Neglecting Refugee Children
“As Doctors Without Borders/Médecins Sans Frontières (MSF) begins vaccinating children against pneumonia in a refugee camp in South Sudan, the international medical humanitarian organization warned today that the global vaccination community is neglecting to provide new vaccines to crisis-affected children.

“While planning to immunize children against pneumococcal diseases in the Yida refugee camp, which is home to close to 100,000 Sudanese refugees, MSF faced multiple barriers to purchasing newer vaccines at an affordable price and struggled to navigate bureaucratic policies that exclude the needs of conflict-affected populations.

“Refugee children are incredibly vulnerable to developing vaccine-preventable diseases, so why do we keep hearing the players in the global vaccination community tell us these kids aren’t their problem,” asked Kate Elder, vaccines policy advisor at MSF’s Access Campaign. “We should be making every effort for refugee children to benefit from the newest vaccines, instead of letting them languish in the global community’s blind spot.

“Newer vaccines have primarily been introduced in poor countries with support from the Global Alliance for Vaccines and Immunization (GAVI Alliance). But GAVI does not cover vaccination in refugee and crisis-affected populations, leaving major needs unmet. Moreover, discounted prices that GAVI is able to negotiate are not systematically available to humanitarian actors working in crisis contexts…
Full text: http://www.doctorswithoutborders.org/press/release.cfm?id=6978&cat=press-release%29

.
GAVI’s statement in response (undated) notes in part:
“The GAVI Alliance congratulates MSF on beginning to vaccinate children with pneumococcal conjugate vaccines (PCV) in the Yida refugee camp in South Sudan. We were pleased to have been able to play a facilitating role in helping MSF procure these vaccines…

“…Our focus is on expanding access to vaccines in a long-term sustainable way and that means working through the governments of the world’s 73 poorest countries to strengthen and expand routine immunisation services for all children.

“South Sudan has yet to apply for GAVI support for PCV but when it does, GAVI will work with the Ministry of Health to help them roll it out sustainably to all children in the country. First, we will support South Sudan to introduce the pentavalent vaccine starting next year (2014)…

“We recognise the importance of vaccines in humanitarian emergencies and where we can add value, we have and will continue to try to help.  For example, soon after we supported the introduction of PCV in Kenya, we supported the Government to provide PCV for Somali children in the Dadaab refugee camp.”
Full text: http://www.gavialliance.org/library/news/statements/2013/gavi-responds-to-medecins-sans-frontieres/

Sabin convenes “senior officials from 17 countries to share their successes in increasing government budget allocations for national immunisation programs”

The Sabin Vaccine Institute’s Sustainable immunisation Financing (SIF) Program said it convened “senior officials from 17 countries to share their successes in increasing government budget allocations for national immunisation programs.” Sabin noted that “greater political commitment and advocacy are building the momentum needed for countries to fully finance their immunisation programs by 2020 and achieve the goals set forth in the Global Vaccine Action Plan (GVAP).”  Delegates to the two-day colloquium “participated in an open exchange of strategies and best practices that have helped their countries increase commitments to fund national immunisation programs.” In panel sessions, delegates presented their legislative activities, conduct peer assessments and discuss innovations in financing, budgeting and advocacy, and were supported in preparing “short-term, country specific advocacy plans designed to make progress on sustainable immunisation financing by 2016.” The 17 countries involved in the colloquium are all SIF pilot countries and included Cameroon, Cambodia, Democratic Republic of Congo, Indonesia, Kenya, Liberia, Madagascar, Mali, Mongolia, Nepal, Nigeria, Republic of Congo, Senegal, Sierra Leone, Sri Lanka, Uganda and Vietnam. SIF partners who attended include WHO, UNICEF, World Bank, GAVI Alliance and the Bill & Melinda Gates Foundation.
http://www.gavialliance.org/library/news/press-releases/2013/dakar-conference-countries-showcase-increased-efforts-to-fund-their-own-immunisation-programs/

Editor’s Note: The media release on this meeting did not indicate whether or when video, transcripts or other meeting summary information will be made available.